Home » Agenda

Agenda

Patient Engagement Solutions & Innovations World Congress 2026 Europe

Transforming Care Through Technology, Empathy, and Collaboration.

London, United Kingdom

Thursday 26th - Friday 27th March 2026

We are delighted to welcome you to our upcoming PATIENT ENGAGEMENT SOLUTIONS & INNOVATIONS World Congress 2026 Europe, hosted by FACILITATE LIVE. This year’s congress focuses on “Transforming Care Through Technology, Empathy, and Collaboration.”

In an era defined by accelerated digital transformation, patient engagement has become a strategic imperative for the pharmaceutical and healthcare sectors. Beyond improving clinical outcomes, it is reshaping how organizations create value, differentiate therapies, and build trust in a data-driven, patient-centric ecosystem.

The convergence of AI, real world evidence, digital therapeutics, and precision medicine is enabling more targeted interventions and personalized care pathways. Connected platforms spanning remote monitoring, predictive analytics, and patient support programs—are transforming engagement across the product lifecycle, from clinical development to post-market management. Patients are now active participants, empowered through access to information, digital tools, and real-time feedback loops that drive better adherence and informed decision-making.

For pharmaceutical leaders, this shift presents an opportunity to integrate patient perspectives into every stage of innovation. Digital trials and decentralized research models expand participation and enhance diversity, while AI-driven insights enable faster recruitment, improved trial design, and more representative data. Post-launch, digital engagement solutions sustain communication, reinforce adherence, and generate real-world data that strengthens value demonstration and market access. As healthcare systems evolve toward value-based and outcomes driven models, patient engagement sits at the intersection of innovation, access, and accountability. Success will depend on the industry’s ability to harness data interoperability, responsible AI, and ethical data governance to ensure transparency, privacy, and equitable participation.

However, challenges remain. Digital inequity, fragmented infrastructures, data silos, and clinician resistance continue to slow progress. Overcoming these barriers will require cross sector collaboration, regulatory alignment, and a shared commitment to patient-centered design. Investment in education, digital literacy, and ecosystem interoperability will be critical to sustaining engagement and trust. At this congress, our goal is to unite leaders across healthcare and life sciences to align on a shared vision for digital maturity and connected care. Together, we will explore actionable strategies to accelerate adoption, measure impact, and scale innovation that truly serves patients.

The next era of healthcare will be defined not just by technological advancement, but by how effectively we integrate empathy, evidence, and innovation to deliver meaningful, measurable outcomes. Patient engagement is no longer optional—it is the foundation of sustainable growth and improved global health.

We look forward to meeting you at the Congress!

Sincerely yours,

Jocelyn Raguindin
Conference Director
Paradigm Global Events / Facilitate Live

GAIN LATEST INSIGHTS ON:

  1. Discover how engagement platforms and digital health innovations are redefining competitive advantage and outcomes in pharma and healthcare.
  2. Learn how to embed patient engagement tools —from education to adherence throughout the clinical and commercial lifecycle.
  3. Explore how patient portals, mobile apps, digital therapeutics, and virtual care solutions enable real time communication and continuous support.
  4. Understand how artificial intelligence and machine learning enhance personalization, predict adherence risk, and enable proactive intervention.
  5. See how engagement technologies generate actionable RWE to inform research, regulatory submissions, and value-based care models.
  6. Examine how decentralized and hybrid trial models use digital engagement to increase diversity, efficiency, and patient retention.
  7. Learn about digital tools, gamification, and behavioral science approaches that improve long term adherence and health outcomes.
  8. Gain insights into blockchain, privacy frameworks, and governance models that ensure trust and compliance across engagement platforms.
  9. Identify strategies to close gaps in access, literacy, and connectivity to ensure engagement solutions reach diverse patient populations.
  10. Understand how pharma, providers, payers, and tech innovators are co creating integrated, scalable engagement ecosystems.
  11. Explore key metrics, benchmarks, and analytics frameworks to quantify the clinical and commercial impact of engagement innovations.
  12. Envision the next phase of patient engagement —where technology, interoperability, and human-centered design converge to deliver compassionate, effective healthcare at scale.

WHO SHOULD ATTEND?

This Congress is beneficial to pharmaceutical, biotech companies, researchers, physicians, patient advocacy groups, regulatory agencies, technology and healthcare companies.

Network with Presidents, Heads/Chiefs, VPs, Directors, and Leaders in the area of:

  • Patients and Caregivers
  • Clinical Research Professionals
  • Clinical Trial Coordinators
  • Patient Advocacy and Engagement
  • Pharmaceutical Marketing and Communication
  • Medical Affairs Executives
  • Regulatory Affairs Specialists
  • Data and Real-World Evidence Analysts
  • Chief Information Officers
  • Chief Technology Officers
  • Software Engineers and App Developers
  • AI, Machine Learning, and Data Analytics Professionals
  • Digital Health Specialists
  • Product Development Leads
  • Doctors, Physicians, and Surgeons
  • Nurses and Nurse Practitioners
  • Allied Health Professionals
  • Hospital and Clinic Administrators
  • Medical Directors and Clinical Managers
  • Patient Experience Officers
  • Care Coordinators
  • Healthcare CEOs, COOs, and Innovation Officers
  • Health Policy Makers and Regulators
  • Public Health Officers
  • Academics and Researchers
  • NGO and Nonprofit Representatives
  • Insurance and Payer Representatives
  • Investors and Venture Capitalists
  • Healthcare Consultants and Analysts
  • Start-up Founders and Entrepreneurs
  • Patient Advocacy Groups

Robert Mitchell-Thain, Chief Executive Officer, PBC Foundation

SCALING PATIENT ENGAGEMENT FOR MEASURABLE IMPACT

  • What frameworks successfully integrate engagement into R&D, commercial, and medical functions?
  • How can organizations operationalize engagement as a strategic business capability?
  • What governance models ensure consistency across markets and therapeutic areas?
  • Which KPIs demonstrate success across enterprise-level engagement programs?

Moderator:

Clara Bentham, Head of Corporate Affairs UK and Ireland, Sanofi

Panellists:

Nikul Bakshi, Research Involvement Lead, Parkinson’s UK

Emma Sutcliffe, Founder, Chief Patient Officer, ISPEP
Marlene Vincent, Global Patient Advocacy Leader, Intercept Pharma
Keith Berelowitz, Founder/CEO, pRxEngage Inc
Rasmus Hjorth, Patient Engagement Director, James Lind Care

  • Engagement with PAGs in Clinical Development Program development
  • Clinical trials- PAG involvement to improve enrolment and retention

David Gillen, Chief Medical Officer, Norgine

  • Identifying “unresolved tensions” between patient reality and health data goals
  • Building a shared language and taxonomy in Digital health that serves people, not just platforms
  • From ‘human in the loop’ to ‘human in the lead’ – identifying the skills and capabilities patients need to develop their own solutions

Derick Mitchell, Executive Director, PFMD

  • Pioneering patient partnerships in a mid-size pharma company: not enough resources – what is the answer?
  • Why it is important to co-create with patients and move beyond patient engagement
  • A story about collaboration with TransCelerate

Vesela Aleksandrova, Clinical Operations Director, Shionogi B.V.

  • In this session, we uncover how empathetic trial design and participant‐focused support drastically improve trial completion
  • Insights on building trust, reducing anxiety, and supporting diverse patient needs.
  • We bridge the gap between protocol design and lived patient experience, revealing what truly keeps participants engaged, motivated, and retained.

Miriam Dervan, Founder & CEO, mdgroup
Louise Spencer, Senior Clinical Manager, mdgroup
Joanne Kelly, Clinical Manager, mdgroup

  • This presentation includes learnings and takeaways from different patient engagement projects.
  • You will hear about what to do and not to do in order to succeed the best way possible with your patient engagement project.

Rasmus Hjorth, Patient Engagement Director, James Lind Care

ENABLING CONNECTED PATIENT EXPERIENCES

  • Why evolve our focus from patient engagement to participation?
  • Embracing Participation as key enabler of system-level change, beyond individual interventions: the Care Lab approach.
  • Real-world missions in action: learnings from experience
  • What mobilisation enables: extending care beyond healthcare institutions.

Marta Lago, Programme Co-lead, Healthcare Systems Transformation, The Care Lab

  • Caregivers bridge fragmented digital healthcare systems, often carrying critical information between hospitals and services because no single, shared record exists.
  • Excluding families from digital records in the name of privacy increases risk, forcing unsafe workarounds like repeated retelling of traumatic histories or reliance on memory in crises.
  • Single-point, consent-based digital care plans can transform care, reducing caregiver burden, improving safety, and enabling true collaboration between families and clinicians.

Hannah Humphrey, Lived Experience Expert, Independent Patient Advocate

  • A pioneering medical cannabis patient perspective on why lived experience must be treated as clinical expertise, not anecdote
  • How decades of patient-led use outside regulated systems created knowledge healthcare can no longer afford to ignore
  • What happens to safety, trust, and outcomes when patient expertise is excluded from innovation
  • Practical lessons for clinicians, industry, and policymakers on partnering with patients as equals in care design

Clark French, Founder, United Patients Alliance (UPA)

PERSONALISED & INTELLIGENT SOLUTIONS

  • Show how Thrive uses patient portals, mobile tools and virtual touchpoints to create real-time, two-way communication, giving people with a brain tumour immediate access to guidance, reassurance and personalised coaching.
  • Demonstrate how continuous, data-informed support empowers patients and caregivers, helping them track symptoms, manage uncertainty, and stay connected to specialist advice between clinical appointments.
  • Highlight the impact of digital therapeutics and structured coaching pathways within Thrive, showing how they improve self-management, emotional well-being, and overall quality of life throughout the brain tumour journey.

Dr Helen Bulbeck, Director of Services & Policy, brainstrust

  • How an end-to-end approach—combining digital diagnostics (M-PREG) with mechanistically targeted therapeutics (MZe786)—can transform the early detection, risk-stratification, and treatment of preeclampsia.
  • Lessons from developing and integrating a full diagnostic-to-therapeutic pathway, including biomarker science, algorithm validation, real-world implementation, and translational drug development.

May Rezai, Chief Operations Officer, MirZyme Therapeutics

  • Why taste and sensory attributes matter
  • Integration into the pharmaceutical development pathway
  • Regulatory expectations and paediatric pathways:
  • Impact on product lifecycle and market access
  • Caregiver and behavioural insights
  • Case learnings from published papers
  • Opportunities for better cross-functional collaboration between formulation, regulatory, and patient-engagement teams to accelerate access

Dr Hend Abdelhakim, Asst Professor, Pharmaceutical Sciences & Healthcare Innovation, GBSH, UCL

  • Critical intersection of technological advancements and the indispensable need for human empathy in various fields
  • Delve into real-world examples of compassionate digital care illustrating how technology can be leveraged to enhance, rather than diminish, genuine human connection and support
  • Provider perspectives on the challenges of engaging individuals in a digitally-driven environment, offering valuable insights into overcoming these hurdles
  • How to effectively integrate innovation with empathy to create more impactful and human-centred solutions.

Moderator:
Olivia Kersey, Sibling Carer, Expert on Equity and learning Disabilities

Panellist:

Hannah Humphrey, Lived Experience Expert, Independent Patient Advocate
Lisa Kerr, Senior Director of Patient Engagement, Evinova
Keith Berelowitz, Founder/CEO, pRxEngage Inc

Robert Mitchell-Thain, Chief Executive Officer, PBC Foundation

ENSURING EQUITY, TRUST & ACCESSIBILITY IN ENGAGEMENT INNOVATION

  • How the current clinical trial distribution system creates bottlenecks, slowing recruitment and limiting scientific representation.
  • Why this isn’t just a vision, but a tangible shift already taking shape, and how Global CTDN is redefining the ecosystem to eliminate the search burden and connect the right trials to the right people, seamlessly.
  • How we’re building the infrastructure enabling smarter trial design, deeper intelligence across the clinical research landscape, and faster, more targeted recruitment.
  • What it means for patients, physicians, and the industry when matching becomes effortless.
  • This isn’t just about technology; it’s about reimagining collaboration, equity, and efficiency in clinical research. Join us to explore how CTDN is turning “what if” into “what’s next.”

Nicholas Brooke, Founder and Executive Director, The Synergist

  • How MSIF adapts and translates global resources through the MS Resource Hub to close topic and language gaps.
  • How global datasets, including the Atlas of MS and new evidence on diagnosis, guide advocacy for early and accurate diagnosis.
  • How mentoring, small grants, and shared case studies strengthen emerging MS organisations in Latin America, Africa, and the MENA region.
  • Design principles that support inclusion: co-creation, clear language, multilingual materials, and formats that work in low-bandwidth settings.

Dr Lydia E Makaroff, Chief Executive, Multiple Sclerosis International Federation

  • Overview of digital patient access platforms across five European countries
  • Comparison of national and regional digital health system models
  • Key lessons on scaling patient engagement and digital health adoption across Europe

John Rayner, Senior Director, EMEA Region, HIMSS

  • What clinical trials can learn from consumer industries about trust, experience, and engagement?
  • Moving beyond digitising old processes to true patient‑centred digital transformation
  • Applying human‑centred design across awareness, consideration, enrolment, and retention
  • How technology and AI can scale personalised, inclusive recruitment without increasing burden

Lisa Kerr, Senior Director of Patient Engagement, Evinova

  • Bringing an always‐on support model to rare disease trials, be present between visits, reduce burden, and respect privacy and choice.
  • Co‐design with patients, caregivers, and sites; cut burden via the Patient Friction Coefficient (PFC); unify tools into one companion.

Claudio Sperandio, Executive Director, Development Strategy and Integration, Alexion

  • A patient engagement strategy is now a business asset
  • Business assets are best delivered by professionals
  • Why we no longer accept ‘passionate’ in our job descriptions

Emma Sutcliffe, Founder, Chief Patient Officer, ISPEP

  • This session looks at a simple but often overlooked truth in clinical research: just because someone is eligible for a trial does not mean they feel ready to join it.
  • It will explore how patients make decisions when faced with complex information, uncertainty, and real-life pressures, and why the design of digital tools can either support that process or make it harder.
  • Using ideas from cognitive load theory, decisional conflict research, and Self-Determination Theory, the session will show how to create tools and pathways that improve clarity, build trust, and preserve patient choice.

Dr. Angelika Grechnaya, Psychological & Behavioural Science Lead, pRxEngage
Keith Berelowitz, Founder/CEO, pRxEngage Inc

ENHANCING COMMUNICATION AND COLLABORATION

  • How can digital platforms improve clarity and timeliness in provider–patient communication?
  • What strategies can ensure that technology enhances human empathy in care interactions?
  • How can clinicians be effectively trained to use digital communication tools while maintaining a personal connection with patients?
  • What role does real-time data sharing play in empowering patients to take a more active role in their healthcare decision-making?

Lara Bloom, President and CEO, The Ehlers-Danlos Society

  • What we built & why: A short, plain‐language animation shown alongside the paper informed consent to help potential participants and their families grasp study aims, treatments, visits, and procedures.
  • Who shaped it: Developed in partnership with a patient panel; aligned with global trial teams to keep clinical accuracy while maximising accessibility.
  • The 2‐year reality: Navigating ethics & legal review, procurement, hosting/IT security, and site enablement.
  • Early signals: Positive investigational site feedback; participant feedback being collected; Adapting the asset for other regions.
  • Equity lens: Designed to address health literacy needs and participation disparities in prostate cancer.
  • Call to industry: A practical blueprint to scale; shared storyboard modules, governance templates, hosting standards, and pooled translation models, so multimedia consent becomes routine, not bespoke.

Marie Pullen, Associate Director, Clinical Operations, MSD (UK)
Gillian Thwaites, Associate Director, Clinical Operations, MSD (UK)

  • The CTDN project aims to support a next-generation clinical research ecosystem that connects & empowers those players driven to optimise clinical trials performance, through deeper and wider patient engagement and ensuring patient and scientific representativeness.

Nicholas Brooke, Founder and Executive Director, The Synergist

  • Trends that will shape engagement leadership in the coming decade.
  • Evolving role of pharmaceutical and healthcare companies in a data-literate patient environment.
  • Emerging technologies that will create a competitive advantage.
  • How can we maintain a human-centered approach to engagement?

Moderator:

Emma Sutcliffe, Founder, Chief Patient Officer, ISPEP

Panellist:
Lara Bloom, President and CEO, The Ehlers-Danlos Society
Lisa Kerr, Senior Director of Patient Engagement, Evinova
Robert Mitchell-Thain, Chief Executive Officer, PBC Foundation

Emma Sutcliffe, Founder, Chief Patient Officer, ISPEP

Scroll to Top
Update cookies preferences